RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...

G protein-coupled receptors (GPCRs), crucial for diverse physiological responses, have traditionally been investigated in ...